Bleakley Financial Group’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.41M Buy
148,942
+19,561
+15% +$156K 0.02% 662
2026
Q2
$1.13M Sell
129,381
-34,191
-21% -$259K 0.01% 615
2026
Q1
$1.25M Buy
+163,572
New +$1.12M 0.02% 475
2025
Q1
– Sell
-14,095
Closed -$36.1K – 724
2024
Q4
$36.1K Sell
14,095
-1,848
-12% -$7.7K ﹤0.01% 1030
2024
Q3
$59.3K Buy
15,943
+137
+0.9% +$634 ﹤0.01% 995
2024
Q2
$100K Buy
15,806
+4,983
+46% +$32.9K ﹤0.01% 952
2024
Q1
$58.1K Buy
+10,823
New +$49K ﹤0.01% 958

Other funds holding IBRX

Bleakley Financial Group's IBRX Position: Q3 2026 in Review

Bleakley Financial Group increased its ImmunityBio (IBRX) stake by 15% in Q3 2026, buying an estimated $156K and bringing the position to 148,942 shares worth $1.41M. The position accounts for 0.02% of the portfolio, ranked #662.

Bleakley Financial Group first reported a position in IBRX in Q1 2024 and has held it in 7 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Bleakley Financial Group held 148,942 shares of ImmunityBio worth $1.41M as of Q3 2026.
  • Bleakley Financial Group bought 19,561 ImmunityBio shares in Q3 2026, an estimated $156K.
  • ImmunityBio made up 0.02% of Bleakley Financial Group's portfolio in Q3 2026, its #662 holding.
  • Bleakley Financial Group first reported a position in ImmunityBio in Q1 2024 and has held it in 7 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Bleakley Financial Group's 13F filing for Q3 2026, filed 13 Nov 2026.